Market: NMS |
Currency: USD
Address: 900 Middlefield Road
Biomea Fusion, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, a covalent inhibitor of menin for treating patients with liquid and solid tumors and type 2 diabetes. The company was incorporated in 2017 and is headquartered in Redwood City, California.
📈 Biomea Fusion, Inc. Historical Chart
📊 Statistics
-
Analyst 1 Year Price Target:
$7.00
-
Upside/Downside from Analyst Target:
422.39%
-
Broker Call:
10
-
Dividend Minimum 3 Year Yield:
0.00%
-
EPS Growth Range (1Y):
25-50%
-
Net Income Growth Range (1Y):
25-50%
-
Revenue Growth Range (1Y):
-
-
Upcoming Earnings Date:
2026-04-01
-
EPS Estimate:
-0.22
💰 Dividend History
No dividend history available.
📅 Earnings & EPS History for Biomea Fusion, Inc.
| Date | Reported EPS |
|---|
| 2026-03-31 (estimated upcoming) | - |
| 2025-11-04 | -0.24 |
| 2025-08-05 | -0.51 |
| 2025-05-05 | -0.8 |
| 2025-03-31 | -0.81 |
| 2024-10-29 | -0.91 |
| 2024-07-31 | -1.03 |
| 2024-05-02 | -1.09 |
| 2024-03-28 | -0.98 |
| 2023-10-30 | -0.8 |
| 2023-07-31 | -0.7 |
| 2023-05-02 | -0.98 |
| 2023-03-28 | -0.86 |
| 2022-11-07 | -0.78 |
| 2022-08-01 | -0.59 |
| 2022-05-16 | -0.56 |
| 2022-02-28 | -0.51 |
| 2021-11-03 | -0.43 |
| 2021-08-11 | -0.33 |
| 2021-05-27 | -0.49 |
📰 Related News & Research
No related articles found for "biomea fusion".
